Recent Finacing
Recent Raise
Curevo is a Seattle-based clinical-stage biotech developing adjuvanted subunit vaccines—lead candidate CRV-101 (amezosvatein) for shingles in Phase 2b head-to-head trials versus Shingrix, plus a non-live chickenpox vaccine.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
